Skip to main content

Market Overview

UPDATE: Cantor Fitzgerald Downgrades Salix Pharmaceuticals on Fair Valuation


In a report published Monday, Cantor Fitzgerald analyst Irina Rivkind downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Hold, but raised the price target from $72.00 to $81.00.

In the report, Cantor Fitzgerald noted, “One of our favorite names is finally fairly valued. We are already giving the company risk-adjusted credit for Xifaxan IBSD, and now added risk-adjusted estimates for Relistor in chronic pain-related opioid-induced constipation (OIC), along with cost-assumptions associated with the company's entry into the primary care space. We also increased our outer year gross margin assumptions to account for the end of the Alfa-Wasserman manufacturing agreement in July 2014. These model changes resulted in a $9 price target increase from $72 to $81. There may be +7% upside remaining, but a downgrade of SLXP from BUY to HOLD is warranted, in our view. Our estimates exclude credit for next-gen Xifaxan for now. We see minimal downside risk to the stock, since (1) we are not expecting the FDA panel to request a large cardiovascular outcomes trial for Relistor; and (2) we think that management has the flexibility to raise Xifaxan Orphan pricing if the IBS-D program is terminated.”

Salix Pharmaceuticals closed on Friday at $75.54.

Latest Ratings for SLXP

Mar 2015JefferiesDowngradesBuyHold
Feb 2015Cantor FitzgeraldDowngradesBuyHold
Feb 2015UBSDowngradesBuyNeutral

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings


Related Articles (SLXP)

View Comments and Join the Discussion!

Posted-In: Cantor Fitzgerald Irina RivkindAnalyst Color Downgrades Analyst Ratings

Latest Ratings

FSRMorgan StanleyMaintains40.0
MEDDA DavidsonMaintains302.0
VICRBWS FinancialMaintains120.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at